Controversy has dogged Sarepta’s Duchenne muscular dystrophy therapy Exondys 51 since its approval, and it’s not out of the woods yet. US cost-effectiveness watchdog the Institute for Clinical ...

Sarepta Therapeutics (NASDAQ ... therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with ...

Lead drug PGN-EDO51 targets a mutation in the dystrophin gene that can be treated by skipping exon 51, making it a potential rival to Sarepta Pharma's Exondys 51 (eteplirsen), which made $454 ...

Check Out Our Latest Stock Analysis on Sarepta Therapeutics Sarepta Therapeutics Stock Down 0.6 % Shares of NASDAQ:SRPT opened at $113.72 on Thursday. Sarepta Therapeutics has a 1 year low of $102 ...

The next-gen Alienware Area 51 is now available to preorder - and it can be yours for the eye-watering price of just $4499.99 - $1,000 of which is likely the brand-new RTX 5080 graphics card that ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.